Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Annals of Oncology, Год журнала: 2023, Номер 34(4), С. 358 - 376

Опубликована: Янв. 17, 2023

Язык: Английский

---

Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC

New England Journal of Medicine, Год журнала: 2023, Номер 389(21), С. 1935 - 1948

Опубликована: Ноя. 8, 2023

Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that selective for EGFR-TKI-sensitizing and

Язык: Английский

---

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

Annals of Oncology, Год журнала: 2023, Номер 35(1), С. 77 - 90

Опубликована: Окт. 23, 2023

Amivantamab plus carboplatin-pemetrexed (chemotherapy) with and without lazertinib demonstrated antitumor activity in patients refractory epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) phase I studies. These combinations were evaluated a global III trial.

Язык: Английский

---

HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy

Journal of Clinical Oncology, Год журнала: 2023, Номер 41(35), С. 5363 - 5375

Опубликована: Сен. 10, 2023

Patritumab deruxtecan, or HER3-DXd, is an antibody-drug conjugate consisting of a fully human monoclonal antibody to epidermal growth factor receptor 3 (HER3) attached topoisomerase I inhibitor payload via stable tetrapeptide-based cleavable linker. We assessed the efficacy and safety HER3-DXd in patients with (

Язык: Английский

---

Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group

Annals of Oncology, Год журнала: 2024, Номер 35(7), С. 588 - 606

Опубликована: Май 27, 2024

Advancements in the field of precision medicine have prompted European Society for Medical Oncology (ESMO) Precision Medicine Working Group to update recommendations use tumour next-generation sequencing (NGS) patients with advanced cancers routine practice.

Язык: Английский

---

Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC

New England Journal of Medicine, Год журнала: 2024, Номер 391(16), С. 1486 - 1498

Опубликована: Июнь 26, 2024

BackgroundAmivantamab plus lazertinib (amivantamab–lazertinib) has shown clinically meaningful and durable antitumor activity in patients with previously untreated or osimertinib-pretreated EGFR (epidermal growth factor receptor)–mutated advanced non–small-cell lung cancer (NSCLC).MethodsIn a phase 3, international, randomized trial, we assigned, 2:2:1 ratio, EGFR-mutated (exon 19 deletion L858R), locally metastatic NSCLC to receive amivantamab–lazertinib (in an open-label fashion), osimertinib blinded fashion, assess the contribution of treatment components). The primary end point was progression-free survival group as compared group, assessed by independent central review.ResultsOverall, 1074 underwent randomization (429 amivantamab–lazertinib, 429 osimertinib, 216 lazertinib). median significantly longer than (23.7 vs. 16.6 months; hazard ratio for disease progression death, 0.70; 95% confidence interval [CI], 0.58 0.85; P<0.001). An objective response observed 86% (95% CI, 83 89) 85% those 81 88) group; among confirmed (336 314 group), duration 25.8 months 20.1 could not be estimated) 16.8 14.8 18.5), respectively. In planned interim overall analysis death 0.80 0.61 1.05). Predominant adverse events were EGFR-related toxic effects. incidence discontinuation all agents due treatment-related 10% 3% osimertinib.ConclusionsAmivantamab–lazertinib showed superior efficacy first-line NSCLC. (Funded Janssen Research Development; MARIPOSA ClinicalTrials.gov number, NCT04487080.)

Язык: Английский

---

Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC

New England Journal of Medicine, Год журнала: 2024, Номер 391(7), С. 585 - 597

Опубликована: Июнь 2, 2024

Osimertinib is a recommended treatment for advanced non-small-cell lung cancer (NSCLC) with an epidermal growth factor receptor (

Язык: Английский

---

Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722

Journal of Clinical Oncology, Год журнала: 2024, Номер 42(11), С. 1252 - 1264

Опубликована: Янв. 22, 2024

PURPOSE The phase III CheckMate 722 trial (ClinicalTrials.gov identifier: NCT02864251 ) evaluated nivolumab plus chemotherapy versus in patients with epidermal growth factor receptor ( EGFR)–mutated metastatic non–small-cell lung cancer (NSCLC) after disease progression on EGFR tyrosine kinase inhibitors (TKIs). METHODS Patients first- or second-generation TKI therapy (without T790M mutation) osimertinib (with/without were randomly assigned 1:1 to (360 mg once every 3 weeks) platinum-doublet (once alone for four cycles. Primary end point was progression-free survival (PFS). Secondary points included 9- and 12-month PFS rates, overall (OS), objective response rate (ORR), duration of (DOR). RESULTS Overall, 294 assigned. At final analysis (median follow-up, 38.1 months), not significantly improved (median, 5.6 v 5.4 months; hazard ratio [HR], 0.75 [95% CI, 0.56 1.00]; P = .0528), rates 25.9% 19.8%, 21.2% 15.9%, respectively. Post hoc subgroup analyses showed a trend favoring tumors harboring sensitizing mutations (HR, 0.72 0.54 0.97]), one line previous (0.72 both (0.64 0.47 0.88]). Median OS 19.4 months 15.9 chemotherapy, while ORR 31.3% 26.7%, median DOR 6.7 months, Grade 3/4 treatment-related adverse events occurred 44.7% 29.4% treated alone, CONCLUSION Nivolumab did improve EGFR-mutated NSCLC previously TKIs. No new safety signals identified.

Язык: Английский

---

Non-small-cell lung cancer

Nature Reviews Disease Primers, Год журнала: 2024, Номер 10(1)

Опубликована: Сен. 26, 2024

Язык: Английский

---

CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor–Mutated Advanced Non–Small-Cell Lung Cancer

Journal of Clinical Oncology, Год журнала: 2023, Номер 42(7), С. 808 - 820

Опубликована: Дек. 3, 2023

We report CNS efficacy of first-line osimertinib plus chemotherapy versus monotherapy in patients with epidermal growth factor receptor (

Язык: Английский

---